世界のうつ病医療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Depression Medicine Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5697 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、うつ病医療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（三環系抗うつ薬、セロトニン-ノルエピネフリン阻害薬、非定型抗精神病薬、選択的セロトニン再取り込み阻害薬、ベンゾジアゼピン、四環系抗うつ薬、モノアミン酸化酵素阻害薬、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・うつ病医療の市場動向 ・企業の競争状況、市場シェア ・うつ病医療の種類別市場規模と予測2016-2027（三環系抗うつ薬、セロトニン-ノルエピネフリン阻害薬、非定型抗精神病薬、選択的セロトニン再取り込み阻害薬、ベンゾジアゼピン、四環系抗うつ薬、モノアミン酸化酵素阻害薬、その他） ・うつ病医療の用途別市場規模と予測2016-2027（病院、診療所、その他） ・うつ病医療の北米市場規模2016-2027（アメリカ、カナダ） ・うつ病医療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・うつ病医療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・うつ病医療の中南米市場規模2016-2027（メキシコ、ブラジル） ・うつ病医療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、AstraZeneca、Eli Lilly and Company、Novartis、GlaxoSmithKline、Otsuka Pharmaceutical、Abbott Laboratories、Gedeon Richter、Janssen Pharmaceuticals、Lupin Pharmaceuticals、Luye Pharma、MSI Methylation Sciences、Naurex、SK Biopharmaceuticals） ・結論

Market Analysis and Insights: Global Depression Medicine Market
The global Depression Medicine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Depression Medicine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Depression Medicine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Depression Medicine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Depression Medicine market.

Global Depression Medicine Scope and Market Size
Depression Medicine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Depression Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Tricyclic Antidepressants
Serotonin-norepinephrine Inhibitors
Atypical Antipsychotics
Selective Serotonin Reuptake Inhibitors
Benzodiazepines
Tetracyclic Antidepressants
Monoamine Oxidase Inhibitors
Others

Segment by Application
Hospitals
Clinics
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
AstraZeneca
Eli Lilly and Company
Novartis
GlaxoSmithKline
Otsuka Pharmaceutical
Abbott Laboratories
Gedeon Richter
Janssen Pharmaceuticals
Lupin Pharmaceuticals
Luye Pharma
MSI Methylation Sciences
Naurex
SK Biopharmaceuticals

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Depression Medicine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tricyclic Antidepressants
1.2.3 Serotonin-norepinephrine Inhibitors
1.2.4 Atypical Antipsychotics
1.2.5 Selective Serotonin Reuptake Inhibitors
1.2.6 Benzodiazepines
1.2.7 Tetracyclic Antidepressants
1.2.8 Monoamine Oxidase Inhibitors
1.2.9 Others
1.3 Market by Application
1.3.1 Global Depression Medicine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Depression Medicine Market Perspective (2016-2027)
2.2 Depression Medicine Growth Trends by Regions
2.2.1 Depression Medicine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Depression Medicine Historic Market Share by Regions (2016-2021)
2.2.3 Depression Medicine Forecasted Market Size by Regions (2022-2027)
2.3 Depression Medicine Industry Dynamic
2.3.1 Depression Medicine Market Trends
2.3.2 Depression Medicine Market Drivers
2.3.3 Depression Medicine Market Challenges
2.3.4 Depression Medicine Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Depression Medicine Players by Revenue
3.1.1 Global Top Depression Medicine Players by Revenue (2016-2021)
3.1.2 Global Depression Medicine Revenue Market Share by Players (2016-2021)
3.2 Global Depression Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Depression Medicine Revenue
3.4 Global Depression Medicine Market Concentration Ratio
3.4.1 Global Depression Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Depression Medicine Revenue in 2020
3.5 Depression Medicine Key Players Head office and Area Served
3.6 Key Players Depression Medicine Product Solution and Service
3.7 Date of Enter into Depression Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Depression Medicine Breakdown Data by Type
4.1 Global Depression Medicine Historic Market Size by Type (2016-2021)
4.2 Global Depression Medicine Forecasted Market Size by Type (2022-2027)

5 Depression Medicine Breakdown Data by Application
5.1 Global Depression Medicine Historic Market Size by Application (2016-2021)
5.2 Global Depression Medicine Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Depression Medicine Market Size (2016-2027)
6.2 North America Depression Medicine Market Size by Type
6.2.1 North America Depression Medicine Market Size by Type (2016-2021)
6.2.2 North America Depression Medicine Market Size by Type (2022-2027)
6.2.3 North America Depression Medicine Market Size by Type (2016-2027)
6.3 North America Depression Medicine Market Size by Application
6.3.1 North America Depression Medicine Market Size by Application (2016-2021)
6.3.2 North America Depression Medicine Market Size by Application (2022-2027)
6.3.3 North America Depression Medicine Market Size by Application (2016-2027)
6.4 North America Depression Medicine Market Size by Country
6.4.1 North America Depression Medicine Market Size by Country (2016-2021)
6.4.2 North America Depression Medicine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Depression Medicine Market Size (2016-2027)
7.2 Europe Depression Medicine Market Size by Type
7.2.1 Europe Depression Medicine Market Size by Type (2016-2021)
7.2.2 Europe Depression Medicine Market Size by Type (2022-2027)
7.2.3 Europe Depression Medicine Market Size by Type (2016-2027)
7.3 Europe Depression Medicine Market Size by Application
7.3.1 Europe Depression Medicine Market Size by Application (2016-2021)
7.3.2 Europe Depression Medicine Market Size by Application (2022-2027)
7.3.3 Europe Depression Medicine Market Size by Application (2016-2027)
7.4 Europe Depression Medicine Market Size by Country
7.4.1 Europe Depression Medicine Market Size by Country (2016-2021)
7.4.2 Europe Depression Medicine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Depression Medicine Market Size (2016-2027)
8.2 Asia-Pacific Depression Medicine Market Size by Type
8.2.1 Asia-Pacific Depression Medicine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Depression Medicine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Depression Medicine Market Size by Type (2016-2027)
8.3 Asia-Pacific Depression Medicine Market Size by Application
8.3.1 Asia-Pacific Depression Medicine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Depression Medicine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Depression Medicine Market Size by Application (2016-2027)
8.4 Asia-Pacific Depression Medicine Market Size by Region
8.4.1 Asia-Pacific Depression Medicine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Depression Medicine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Depression Medicine Market Size (2016-2027)
9.2 Latin America Depression Medicine Market Size by Type
9.2.1 Latin America Depression Medicine Market Size by Type (2016-2021)
9.2.2 Latin America Depression Medicine Market Size by Type (2022-2027)
9.2.3 Latin America Depression Medicine Market Size by Type (2016-2027)
9.3 Latin America Depression Medicine Market Size by Application
9.3.1 Latin America Depression Medicine Market Size by Application (2016-2021)
9.3.2 Latin America Depression Medicine Market Size by Application (2022-2027)
9.3.3 Latin America Depression Medicine Market Size by Application (2016-2027)
9.4 Latin America Depression Medicine Market Size by Country
9.4.1 Latin America Depression Medicine Market Size by Country (2016-2021)
9.4.2 Latin America Depression Medicine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Depression Medicine Market Size (2016-2027)
10.2 Middle East & Africa Depression Medicine Market Size by Type
10.2.1 Middle East & Africa Depression Medicine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Depression Medicine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Depression Medicine Market Size by Type (2016-2027)
10.3 Middle East & Africa Depression Medicine Market Size by Application
10.3.1 Middle East & Africa Depression Medicine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Depression Medicine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Depression Medicine Market Size by Application (2016-2027)
10.4 Middle East & Africa Depression Medicine Market Size by Country
10.4.1 Middle East & Africa Depression Medicine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Depression Medicine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Depression Medicine Introduction
11.1.4 Pfizer Revenue in Depression Medicine Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Depression Medicine Introduction
11.2.4 AstraZeneca Revenue in Depression Medicine Business (2016-2021)
11.2.5 AstraZeneca Recent Development
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Details
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Depression Medicine Introduction
11.3.4 Eli Lilly and Company Revenue in Depression Medicine Business (2016-2021)
11.3.5 Eli Lilly and Company Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Depression Medicine Introduction
11.4.4 Novartis Revenue in Depression Medicine Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Depression Medicine Introduction
11.5.4 GlaxoSmithKline Revenue in Depression Medicine Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Otsuka Pharmaceutical
11.6.1 Otsuka Pharmaceutical Company Details
11.6.2 Otsuka Pharmaceutical Business Overview
11.6.3 Otsuka Pharmaceutical Depression Medicine Introduction
11.6.4 Otsuka Pharmaceutical Revenue in Depression Medicine Business (2016-2021)
11.6.5 Otsuka Pharmaceutical Recent Development
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Company Details
11.7.2 Abbott Laboratories Business Overview
11.7.3 Abbott Laboratories Depression Medicine Introduction
11.7.4 Abbott Laboratories Revenue in Depression Medicine Business (2016-2021)
11.7.5 Abbott Laboratories Recent Development
11.8 Gedeon Richter
11.8.1 Gedeon Richter Company Details
11.8.2 Gedeon Richter Business Overview
11.8.3 Gedeon Richter Depression Medicine Introduction
11.8.4 Gedeon Richter Revenue in Depression Medicine Business (2016-2021)
11.8.5 Gedeon Richter Recent Development
11.9 Janssen Pharmaceuticals
11.9.1 Janssen Pharmaceuticals Company Details
11.9.2 Janssen Pharmaceuticals Business Overview
11.9.3 Janssen Pharmaceuticals Depression Medicine Introduction
11.9.4 Janssen Pharmaceuticals Revenue in Depression Medicine Business (2016-2021)
11.9.5 Janssen Pharmaceuticals Recent Development
11.10 Lupin Pharmaceuticals
11.10.1 Lupin Pharmaceuticals Company Details
11.10.2 Lupin Pharmaceuticals Business Overview
11.10.3 Lupin Pharmaceuticals Depression Medicine Introduction
11.10.4 Lupin Pharmaceuticals Revenue in Depression Medicine Business (2016-2021)
11.10.5 Lupin Pharmaceuticals Recent Development
11.11 Luye Pharma
11.11.1 Luye Pharma Company Details
11.11.2 Luye Pharma Business Overview
11.11.3 Luye Pharma Depression Medicine Introduction
11.11.4 Luye Pharma Revenue in Depression Medicine Business (2016-2021)
11.11.5 Luye Pharma Recent Development
11.12 MSI Methylation Sciences
11.12.1 MSI Methylation Sciences Company Details
11.12.2 MSI Methylation Sciences Business Overview
11.12.3 MSI Methylation Sciences Depression Medicine Introduction
11.12.4 MSI Methylation Sciences Revenue in Depression Medicine Business (2016-2021)
11.12.5 MSI Methylation Sciences Recent Development
11.13 Naurex
11.13.1 Naurex Company Details
11.13.2 Naurex Business Overview
11.13.3 Naurex Depression Medicine Introduction
11.13.4 Naurex Revenue in Depression Medicine Business (2016-2021)
11.13.5 Naurex Recent Development
11.14 SK Biopharmaceuticals
11.14.1 SK Biopharmaceuticals Company Details
11.14.2 SK Biopharmaceuticals Business Overview
11.14.3 SK Biopharmaceuticals Depression Medicine Introduction
11.14.4 SK Biopharmaceuticals Revenue in Depression Medicine Business (2016-2021)
11.14.5 SK Biopharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Depression Medicine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tricyclic Antidepressants
Table 3. Key Players of Serotonin-norepinephrine Inhibitors
Table 4. Key Players of Atypical Antipsychotics
Table 5. Key Players of Selective Serotonin Reuptake Inhibitors
Table 6. Key Players of Benzodiazepines
Table 7. Key Players of Tetracyclic Antidepressants
Table 8. Key Players of Monoamine Oxidase Inhibitors
Table 9. Key Players of Others
Table 10. Global Depression Medicine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Depression Medicine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 12. Global Depression Medicine Market Size by Regions (2016-2021) & (US$ Million)
Table 13. Global Depression Medicine Market Share by Regions (2016-2021)
Table 14. Global Depression Medicine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 15. Global Depression Medicine Market Share by Regions (2022-2027)
Table 16. Depression Medicine Market Trends
Table 17. Depression Medicine Market Drivers
Table 18. Depression Medicine Market Challenges
Table 19. Depression Medicine Market Restraints
Table 20. Global Depression Medicine Revenue by Players (2016-2021) & (US$ Million)
Table 21. Global Depression Medicine Market Share by Players (2016-2021)
Table 22. Global Top Depression Medicine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Depression Medicine as of 2020)
Table 23. Ranking of Global Top Depression Medicine Companies by Revenue (US$ Million) in 2020
Table 24. Global 5 Largest Players Market Share by Depression Medicine Revenue (CR5 and HHI) & (2016-2021)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Depression Medicine Product Solution and Service
Table 27. Date of Enter into Depression Medicine Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Depression Medicine Market Size by Type (2016-2021) (US$ Million)
Table 30. Global Depression Medicine Revenue Market Share by Type (2016-2021)
Table 31. Global Depression Medicine Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 32. Global Depression Medicine Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 33. Global Depression Medicine Market Size Share by Application (2016-2021) & (US$ Million)
Table 34. Global Depression Medicine Revenue Market Share by Application (2016-2021)
Table 35. Global Depression Medicine Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 36. Global Depression Medicine Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 37. North America Depression Medicine Market Size by Type (2016-2021) (US$ Million)
Table 38. North America Depression Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 39. North America Depression Medicine Market Size by Application (2016-2021) (US$ Million)
Table 40. North America Depression Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 41. North America Depression Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 42. North America Depression Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 43. Europe Depression Medicine Market Size by Type (2016-2021) (US$ Million)
Table 44. Europe Depression Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 45. Europe Depression Medicine Market Size by Application (2016-2021) (US$ Million)
Table 46. Europe Depression Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 47. Europe Depression Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 48. Europe Depression Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Depression Medicine Market Size by Type (2016-2021) (US$ Million)
Table 50. Asia-Pacific Depression Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Depression Medicine Market Size by Application (2016-2021) (US$ Million)
Table 52. Asia-Pacific Depression Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 53. Asia-Pacific Depression Medicine Market Size by Region (2016-2021) & (US$ Million)
Table 54. Asia-Pacific Depression Medicine Market Size by Region (2022-2027) & (US$ Million)
Table 55. Latin America Depression Medicine Market Size by Type (2016-2021) (US$ Million)
Table 56. Latin America Depression Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 57. Latin America Depression Medicine Market Size by Application (2016-2021) (US$ Million)
Table 58. Latin America Depression Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 59. Latin America Depression Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 60. Latin America Depression Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Depression Medicine Market Size by Type (2016-2021) (US$ Million)
Table 62. Middle East & Africa Depression Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Depression Medicine Market Size by Application (2016-2021) (US$ Million)
Table 64. Middle East & Africa Depression Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 65. Middle East & Africa Depression Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 66. Middle East & Africa Depression Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer Depression Medicine Product
Table 70. Pfizer Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. AstraZeneca Company Details
Table 73. AstraZeneca Business Overview
Table 74. AstraZeneca Depression Medicine Product
Table 75. AstraZeneca Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 76. AstraZeneca Recent Development
Table 77. Eli Lilly and Company Company Details
Table 78. Eli Lilly and Company Business Overview
Table 79. Eli Lilly and Company Depression Medicine Product
Table 80. Eli Lilly and Company Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 81. Eli Lilly and Company Recent Development
Table 82. Novartis Company Details
Table 83. Novartis Business Overview
Table 84. Novartis Depression Medicine Product
Table 85. Novartis Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 86. Novartis Recent Development
Table 87. GlaxoSmithKline Company Details
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Depression Medicine Product
Table 90. GlaxoSmithKline Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 91. GlaxoSmithKline Recent Development
Table 92. Otsuka Pharmaceutical Company Details
Table 93. Otsuka Pharmaceutical Business Overview
Table 94. Otsuka Pharmaceutical Depression Medicine Product
Table 95. Otsuka Pharmaceutical Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 96. Otsuka Pharmaceutical Recent Development
Table 97. Abbott Laboratories Company Details
Table 98. Abbott Laboratories Business Overview
Table 99. Abbott Laboratories Depression Medicine Product
Table 100. Abbott Laboratories Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 101. Abbott Laboratories Recent Development
Table 102. Gedeon Richter Company Details
Table 103. Gedeon Richter Business Overview
Table 104. Gedeon Richter Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 105. Gedeon Richter Recent Development
Table 106. Janssen Pharmaceuticals Company Details
Table 107. Janssen Pharmaceuticals Business Overview
Table 108. Janssen Pharmaceuticals Depression Medicine Product
Table 109. Janssen Pharmaceuticals Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 110. Janssen Pharmaceuticals Recent Development
Table 111. Lupin Pharmaceuticals Company Details
Table 112. Lupin Pharmaceuticals Business Overview
Table 113. Lupin Pharmaceuticals Depression Medicine Product
Table 114. Lupin Pharmaceuticals Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 115. Lupin Pharmaceuticals Recent Development
Table 116. Luye Pharma Company Details
Table 117. Luye Pharma Business Overview
Table 118. Luye Pharma Depression Medicine Product
Table 119. Luye Pharma Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 120. Luye Pharma Recent Development
Table 121. MSI Methylation Sciences Company Details
Table 122. MSI Methylation Sciences Business Overview
Table 123. MSI Methylation Sciences Depression Medicine Product
Table 124. MSI Methylation Sciences Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 125. MSI Methylation Sciences Recent Development
Table 126. Naurex Company Details
Table 127. Naurex Business Overview
Table 128. Naurex Depression Medicine Product
Table 129. Naurex Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 130. Naurex Recent Development
Table 131. SK Biopharmaceuticals Company Details
Table 132. SK Biopharmaceuticals Business Overview
Table 133. SK Biopharmaceuticals Depression Medicine Product
Table 134. SK Biopharmaceuticals Revenue in Depression Medicine Business (2016-2021) & (US$ Million)
Table 135. SK Biopharmaceuticals Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Depression Medicine Market Share by Type: 2020 VS 2027
Figure 2. Tricyclic Antidepressants Features
Figure 3. Serotonin-norepinephrine Inhibitors Features
Figure 4. Atypical Antipsychotics Features
Figure 5. Selective Serotonin Reuptake Inhibitors Features
Figure 6. Benzodiazepines Features
Figure 7. Tetracyclic Antidepressants Features
Figure 8. Monoamine Oxidase Inhibitors Features
Figure 9. Others Features
Figure 10. Global Depression Medicine Market Share by Application: 2020 VS 2027
Figure 11. Hospitals Case Studies
Figure 12. Clinics Case Studies
Figure 13. Others Case Studies
Figure 14. Depression Medicine Report Years Considered
Figure 15. Global Depression Medicine Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Depression Medicine Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Depression Medicine Market Share by Regions: 2020 VS 2027
Figure 18. Global Depression Medicine Market Share by Regions (2022-2027)
Figure 19. Global Depression Medicine Market Share by Players in 2020
Figure 20. Global Top Depression Medicine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Depression Medicine as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Depression Medicine Revenue in 2020
Figure 22. Global Depression Medicine Revenue Market Share by Type (2016-2021)
Figure 23. Global Depression Medicine Revenue Market Share by Type (2022-2027)
Figure 24. North America Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Depression Medicine Market Share by Type (2016-2027)
Figure 26. North America Depression Medicine Market Share by Application (2016-2027)
Figure 27. North America Depression Medicine Market Share by Country (2016-2027)
Figure 28. United States Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Depression Medicine Market Share by Type (2016-2027)
Figure 32. Europe Depression Medicine Market Share by Application (2016-2027)
Figure 33. Europe Depression Medicine Market Share by Country (2016-2027)
Figure 34. Germany Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Depression Medicine Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Depression Medicine Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Depression Medicine Market Share by Region (2016-2027)
Figure 44. China Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Depression Medicine Market Share by Type (2016-2027)
Figure 52. Latin America Depression Medicine Market Share by Application (2016-2027)
Figure 53. Latin America Depression Medicine Market Share by Country (2016-2027)
Figure 54. Mexico Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Depression Medicine Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Depression Medicine Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Depression Medicine Market Share by Country (2016-2027)
Figure 60. Turkey Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Depression Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Pfizer Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 64. AstraZeneca Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 65. Eli Lilly and Company Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 68. Otsuka Pharmaceutical Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 69. Abbott Laboratories Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 70. Gedeon Richter Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 71. Janssen Pharmaceuticals Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 72. Lupin Pharmaceuticals Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 73. Luye Pharma Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 74. MSI Methylation Sciences Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 75. Naurex Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 76. SK Biopharmaceuticals Revenue Growth Rate in Depression Medicine Business (2016-2021)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

---